ClinicalTrials.gg
Enrolling by invitationNCT07534696Updated Oct 5, 2026

Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy

An interventional study of Non-invasive pelvic floor neuromuscular stimulation in Urinary Incontinence and Prostatectomy, sponsored by University of California, Los Angeles. Enrolling by invitation at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.

Planned enrollment
165th of 249
37 · median 75
Started
2026
with 10 others
No phase
144 of 293
21 open now
Primary completion
2026-12
later than 18 of 46 live
Registered
288th of 293
by date

Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 165th largest by planned enrollment of the 249 interventional ones that give a count, is one of 11 that started in 2026, is one of 144 with no phase, reaches primary completion later than 18 of the 46 other live ones, and was the 288th registered.

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Urinary Incontinence with a site in United States, or all of them as a file.
02

Study summary

Urinary incontinence is a common complication following prostatectomy and affects a substantial proportion of patients. Despite advances in surgical technique, many patients experience persistent symptoms that negatively impact quality of life. Current management strategies include pelvic floor muscle training, biofeedback and physical therapy, and surgical options. However, these approaches may be limited by adherence, access, and invasiveness, leaving a subset of patients with ongoing symptoms despite standard care.

Non-invasive pelvic floor neuromuscular stimulation has emerged as a potential adjunct for pelvic floor rehabilitation by inducing supramaximal muscle contractions and enhancing neuromuscular activation without requiring active patient effort. Preliminary studies suggest that high-intensity electromagnetic stimulation may improve patient-reported continence outcomes and pad usage in women as well as men following radical prostatectomy, though existing data are limited by small sample sizes and short follow-up durations. Additionally, no clinical studies exist evaluating outcomes in men following prostatectomy prior to established stress incontinence.

Given these limitations, further evaluation is needed to assess the feasibility, tolerability, and short-term effectiveness of this intervention in a post-prostatectomy population.

Read the detailed description

This prospective study aims to evaluate feasibility, safety, and patient-reported continence outcomes associated with non-invasive pelvic floor neuromuscular stimulation in men with urinary incontinence following prostatectomy. Findings may inform future clinical implementation and guide the design of larger, controlled trials.

03

Conditions studied

  • Urinary Incontinence
  • Prostatectomy

Browse trials for

Keywords

  • Neuromuscular stimulation
  • HIFEM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 18 years or older
  • Undergoing or underwent prostatectomy at UCLA
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Cardiac pacemaker, implanted defibrillator, or other metallic or electronic implants
  • Active urinary tract infection
  • Hematuria of unknown origin
  • Untreated bladder outlet obstruction
  • Neurologic conditions affecting bladder function (e.g., multiple sclerosis, Parkinson disease, spinal cord injury)
  • Active fever or systemic inflammatory condition at the time of treatment
  • Any condition deemed by the investigator to make participation unsafe
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    Non-invasive pelvic floor neuromuscular stimulation

    Participants will complete an 8-week intervention (12 sessions total) of non-invasive pelvic floor neuromuscular stimulation, with outcomes assessed at baseline, end of treatment, and follow-up within three months of starting the intervention.

    Device: Non-invasive pelvic floor neuromuscular stimulation

Interventions

  • DeviceNon-invasive pelvic floor neuromuscular stimulation

    Participants will complete an 8-week intervention (12 sessions total), with outcomes assessed at baseline, end of treatment, and follow-up within three months of starting the intervention.

06

What researchers measure

Primary outcomes

  1. Change in EPIC questionnaire score

    The Expanded Prostate Cancer Index Composite (EPIC) is a validated questionnaire assessing urinary, bowel, sexual, and hormonal outcomes.

    Time frame: From enrollment to 3 months after initiation of treatment

  2. Change in ICIQ-UI questionnaire score

    The International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ-UI) short form is a validated questionnaire assessing urinary incontinence.

    Time frame: From enrollment to 3 months after initiation of treatment

  3. Continence

    Continence is measured by number of pads used per 24 hours, with continence defined as less than one pad used per day.

    Time frame: From enrollment to 3 months after initiation of treatment

Secondary outcomes

  1. Treatment failure

    Treatment failure is defined as requiring procedural or surgical intervention for urinary incontinence following prostatectomy.

    Time frame: From enrollment to 3 months after initiation of treatment

07

Study locations

1 site
  • UCLA The Men's Clinic
    Santa Monica, California 90403, United States
08

References and documents

Publications

  • Tosun H, Akinsal EC, Bas U, Sonmez G, Baydilli N, Demirci D. Evaluating the Efficacy of High-Intensity Focused Electromagnetic (HIFEM) Therapy for Postprostatectomy Incontinence in Men. Ther Clin Risk Manag. 2025 Aug 30;21:1309-1315. doi: 10.2147/TCRM.S534674. eCollection 2025. PubMed 40909763 ↗
  • Samuels JB, Pezzella A, Berenholz J, Alinsod R. Safety and Efficacy of a Non-Invasive High-Intensity Focused Electromagnetic Field (HIFEM) Device for Treatment of Urinary Incontinence and Enhancement of Quality of Life. Lasers Surg Med. 2019 Nov;51(9):760-766. doi: 10.1002/lsm.23106. Epub 2019 Jun 7. PubMed 31172580 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 303 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 7 months is below that.

Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 16, 2026
StartActual
May 20, 2026
Primary completionEst.
Dec 31, 2026was Aug 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Dec 31, 2026
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Aug 31, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07534696
Responsible party
Jesse N. Mills, MD (Clinical Professor of Urology, University of California, Los Angeles) — Principal investigator
First posted
Apr 16, 2026
Start date
May 20, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion